12:00 AM
Dec 03, 2007
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oxygent perflubron: Phase IIb discontinued

ALLP discontinued a double-blind, placebo-controlled, dose-escalation, French Phase IIb trial in 128 patients in order to focus on developing Oxygent in China. Beijing Double-Crane Pharmaceutical Co. Ltd. (Beijing,...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >